Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sirexatamab by Leap Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
Sirexatamab by Leap Therapeutics for Esophageal Cancer: Likelihood of Approval
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Sirexatamab by Leap Therapeutics for Endometrial Cancer: Likelihood of Approval
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Sirexatamab by Leap Therapeutics for Gastric Cancer: Likelihood of Approval
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
Sirexatamab by Leap Therapeutics for Colorectal Cancer: Likelihood of Approval
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Leap Therapeutics's Sirexatamab?
Sirexatamab is a monoclonal antibody commercialized by Leap Therapeutics, with a leading Phase II program in Gastric Cancer. According to...
Risk adjusted net present value: What is the current valuation of Leap Therapeutics's Sirexatamab?
Sirexatamab is a monoclonal antibody commercialized by Leap Therapeutics, with a leading Phase II program in Adenocarcinoma Of The Gastroesophageal...